Assembly Biosciences (ASMB) Liabilities and Shareholders Equity (2010 - 2026)

Assembly Biosciences' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $235.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 137.85% year-over-year to $235.5 million; the TTM figure through Mar 2026 stood at $813.9 million (up 87.63% YoY), while the FY2025 annual figure was $257.6 million, up 116.16% from the prior year.
• Liabilities and Shareholders Equity was $235.5 million for Q1 2026 at Assembly Biosciences, down from $257.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $257.6 million in Q4 2025 to a low of $51.6 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $131.5 million across 5 years, with a median of $119.2 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity sank 57.51% in 2023, then soared 139.37% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $101.8 million in 2022, then soared by 34.41% to $136.8 million in 2023, then decreased by 12.9% to $119.2 million in 2024, then soared by 116.16% to $257.6 million in 2025, then retreated by 8.57% to $235.5 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $235.5 million (Q1 2026), $257.6 million (Q4 2025), and $240.0 million (Q3 2025), per Business Quant data.